Auris Medical Holding AG Company Profile (NASDAQ:EARS)

About Auris Medical Holding AG (NASDAQ:EARS)

Auris Medical Holding AG logoAuris Medical Holding AG is a holding and clinical-stage biopharmaceutical company focused on the development of products for the treatment of inner ear disorders. Its advanced product candidate, AM-101, is in Phase III clinical development for acute inner ear tinnitus under a special protocol assessment (SPA) from the United States Food and Drug Administration. Its second product candidate, AM-111, is being developed for the treatment of acute sensorineural hearing loss (ASNHL). It intends to conduct over two pivotal Phase III trials in the treatment of idiopathic sudden SNHL (ISSNHL), titled Acute Inner Ear Hearing Loss (HEALOS) and Acute Sudden Sensorineural Hearing Loss Treatment (ASSENT). AM-111 received orphan drug designation for the treatment of ASNHL from the United States Food and Drug Administration, and the European Union agency. It intends to conduct a Phase II trial in the treatment of surgery-induced hearing loss (REACH).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Bio Therapeutic Drugs
  • Sub-Industry: N/A
  • Symbol: NASDAQ:EARS
  • CUSIP: N/A
  • Web: www.aurismedical.com
Capitalization:
  • Market Cap: $36.13 million
  • Outstanding Shares: 44,329,000
Average Prices:
  • 50 Day Moving Avg: $0.71
  • 200 Day Moving Avg: $0.75
  • 52 Week Range: $0.60 - $1.80
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.85
  • P/E Growth: 0.000
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.13 per share
  • Price / Book: 6.47
Profitability:
  • EBIDTA: ($28,460,000.00)
  • Return on Equity: -218.83%
  • Return on Assets: -75.79%
Debt:
  • Debt-to-Equity Ratio: 1.43%
  • Current Ratio: 2.56%
  • Quick Ratio: 2.56%
Misc:
  • Average Volume: 316,975 shs.
  • Beta: 0.76
  • Short Ratio: 1.62
 

Frequently Asked Questions for Auris Medical Holding AG (NASDAQ:EARS)

What is Auris Medical Holding AG's stock symbol?

Auris Medical Holding AG trades on the NASDAQ under the ticker symbol "EARS."

How were Auris Medical Holding AG's earnings last quarter?

Auris Medical Holding AG (NASDAQ:EARS) issued its quarterly earnings results on Thursday, August, 10th. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.21) by $0.09. View Auris Medical Holding AG's Earnings History.

When will Auris Medical Holding AG make its next earnings announcement?

Auris Medical Holding AG is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for Auris Medical Holding AG.

Where is Auris Medical Holding AG's stock going? Where will Auris Medical Holding AG's stock price be in 2017?

3 equities research analysts have issued twelve-month price targets for Auris Medical Holding AG's stock. Their predictions range from $4.00 to $5.00. On average, they anticipate Auris Medical Holding AG's stock price to reach $4.50 in the next year. View Analyst Ratings for Auris Medical Holding AG.

What are analysts saying about Auris Medical Holding AG stock?

Here are some recent quotes from research analysts about Auris Medical Holding AG stock:

  • 1. According to Zacks Investment Research, "Auris Medical Holding AG is a biopharmaceutical company. It focuses on developing therapies for the treatment of hearing loss and tinnitus. The Company has two projects in advanced clinical development: AM-101 for the treatment of acute inner ear tinnitus and AM-111 for the treatment of acute inner ear hearing loss. Auris Medical Holding AG is headquartered in Zug, Switzerland. " (8/30/2017)
  • 2. Needham & Company LLC analysts commented, "EARS reported 4Q16 financials and update its three ongoing development programs. The next key data catalyst for EARS will be ph 3 HEALOS results for AM-111 (hearing loss) in 3Q17. The study, which should complete enrollment in 2Q17, is the first of two AM-111 pivotal studies in hearing loss. The Keyzilen program will first report results from the open-label studies (AMPACT-1 and 2) in 2Q17 while the recently modified TACCT3 study is on track to have top-line results in 1Q18. EARS plans to evaluate AM-125 (Meniere's disease/vertigo) in an additional ph 1 trial (initiating in 2H17) prior to discussing a regulatory pathway with regulatory authorities. The current EARS market valuation appears to place minimal to no value on any of the ongoing clinical programs.We maintain our Buy rating and adjust our $PT to $4 (from $5)." (3/14/2017)

Who are some of Auris Medical Holding AG's key competitors?

Who are Auris Medical Holding AG's key executives?

Auris Medical Holding AG's management team includes the folowing people:

  • Thomas Meyer, Chairman of the Board, Chief Executive Officer
  • Hernan Levett, Chief Financial Officer
  • Anne Sabine Zoller, General Counsel
  • Cindy McGee, Head of Investor Relations and Corporate Communications
  • Andrea Braun, Head of Regulatory and Quality Affairs
  • Thomas Jung M.D., Ph.D., Chief Development Officer
  • Bettina Mirella Stubinski, Chief Medical Officer
  • James I. Healy M.D. Ph.D., Non-Executive Independent Vice Chairman of the Board
  • Wolfgang Arnold, Non-Executive Independent Director
  • Oliver Kubli, Non-Executive Independent Director

Who owns Auris Medical Holding AG stock?

Auris Medical Holding AG's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Sofinnova Management VIII L.L.C. (17.64%), UBS Oconnor LLC (1.81%), Tekla Capital Management LLC (1.75%) and Virtu KCG Holdings LLC (0.32%). View Institutional Ownership Trends for Auris Medical Holding AG.

Who sold Auris Medical Holding AG stock? Who is selling Auris Medical Holding AG stock?

Auris Medical Holding AG's stock was sold by a variety of institutional investors in the last quarter, including UBS Oconnor LLC. View Insider Buying and Selling for Auris Medical Holding AG.

Who bought Auris Medical Holding AG stock? Who is buying Auris Medical Holding AG stock?

Auris Medical Holding AG's stock was acquired by a variety of institutional investors in the last quarter, including Virtu KCG Holdings LLC. View Insider Buying and Selling for Auris Medical Holding AG.

How do I buy Auris Medical Holding AG stock?

Shares of Auris Medical Holding AG can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Auris Medical Holding AG's stock price today?

One share of Auris Medical Holding AG stock can currently be purchased for approximately $0.82.


MarketBeat Community Rating for Auris Medical Holding AG (NASDAQ EARS)
Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  85 (Vote Outperform)
Underperform Votes:  56 (Vote Underperform)
Total Votes:  141
MarketBeat's community ratings are surveys of what our community members think about Auris Medical Holding AG and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Auris Medical Holding AG (NASDAQ:EARS) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Hold Rating, 2 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $4.50 (452.15% upside)

Analysts' Ratings History for Auris Medical Holding AG (NASDAQ:EARS)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/1/2017Roth CapitalReiterated RatingBuy$5.00LowView Rating Details
3/14/2017Needham & Company LLCLower Price TargetBuy$5.00 -> $4.00HighView Rating Details
11/11/2016JMP SecuritiesReiterated RatingHoldN/AView Rating Details
6/15/2016Leerink SwannReiterated RatingBuy$12.00N/AView Rating Details
6/10/2016Jefferies Group LLCReiterated RatingBuyN/AView Rating Details
(Data available from 9/22/2015 forward)

Earnings

Earnings History for Auris Medical Holding AG (NASDAQ:EARS)
Earnings by Quarter for Auris Medical Holding AG (NASDAQ:EARS)
Earnings History by Quarter for Auris Medical Holding AG (NASDAQ EARS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017($0.17)N/AView Earnings Details
8/10/20176/30/2017($0.21)($0.12)ViewN/AView Earnings Details
5/11/20173/31/2017($0.14)($0.22)ViewN/AView Earnings Details
3/14/201712/31/2016($0.29)($0.16)ViewN/AView Earnings Details
11/10/2016Q316($0.28)($0.23)ViewListenView Earnings Details
5/11/2016Q116($0.23)($0.26)ViewListenView Earnings Details
3/14/2016Q415($0.29)($0.16)ViewListenView Earnings Details
11/12/2015Q315($0.28)($0.16)ViewListenView Earnings Details
8/19/2015Q215($0.23)($0.36)ViewListenView Earnings Details
5/28/2015Q115($0.22)($0.29)ViewListenView Earnings Details
3/19/2015Q4($0.23)($0.17)ViewListenView Earnings Details
12/3/2014Q3($0.24)($0.14)ViewN/AView Earnings Details
9/15/2014Q2 2014($0.34)($0.29)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Auris Medical Holding AG (NASDAQ:EARS)
Current Year EPS Consensus Estimate: $-0.630 EPS
Next Year EPS Consensus Estimate: $-0.440 EPS

Dividends

Dividend History for Auris Medical Holding AG (NASDAQ:EARS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Auris Medical Holding AG (NASDAQ:EARS)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Auris Medical Holding AG (NASDAQ:EARS)
Latest Headlines for Auris Medical Holding AG (NASDAQ:EARS)
Source:
DateHeadline
reuters.com logoBRIEF-Auris Medical completes patient recruitment for phase 3 trial of Keyzilen in acute and post-acute tinnitus
www.reuters.com - September 22 at 5:10 PM
streetinsider.com logoAuris Medical Holding (EARS) Reports Patient Recruitment for Phase 3 TACTT3 Trial of Keyzilen - StreetInsider.com
www.streetinsider.com - September 22 at 8:46 AM
finance.yahoo.com logoAuris Medical Completes Patient Recruitment for Phase 3 TACTT3 Trial of Keyzilen® in Acute and Post-Acute Tinnitus
finance.yahoo.com - September 22 at 8:46 AM
finance.yahoo.com logoAuris Medical to Present at the LEERINK Partners Rare Disease Roundtable Series on September 27
finance.yahoo.com - September 20 at 7:00 PM
finance.yahoo.com logoWhy Auris Medical Holding AG (EARS) Could Be A Buy
finance.yahoo.com - September 15 at 11:43 PM
americanbankingnews.com logo-$0.20 EPS Expected for Auris Medical Holding AG (EARS) This Quarter
www.americanbankingnews.com - September 13 at 4:30 PM
globenewswire.com logoAuris Medical to Host Scientific Symposium at the AAO-HNSF ... - GlobeNewswire (press release)
globenewswire.com - September 6 at 5:51 AM
finance.yahoo.com logoAuris Medical to Host Scientific Symposium at the AAO-HNSF Annual Meeting
finance.yahoo.com - September 5 at 7:44 PM
americanbankingnews.com logoAuris Medical Holding AG (EARS) Upgraded at Zacks Investment Research
www.americanbankingnews.com - August 30 at 8:46 PM
globenewswire.com logoAuris Medical Announces Receipt of Nasdaq Notice - GlobeNewswire (press release)
globenewswire.com - August 25 at 12:05 AM
seekingalpha.com logoAuris Medical short of listing Nasdaq listing requirement of minimum SE
seekingalpha.com - August 24 at 7:02 PM
finance.yahoo.com logoAuris Medical Announces Receipt of Nasdaq Notice
finance.yahoo.com - August 24 at 7:02 PM
finance.yahoo.com logoEdited Transcript of EARS earnings conference call or presentation 10-Aug-17 12:00pm GMT
finance.yahoo.com - August 11 at 6:37 PM
globenewswire.com logoAuris Medical Provides Business Update and Reports Second ... - GlobeNewswire (press release)
globenewswire.com - August 11 at 12:26 AM
americanbankingnews.com logoAuris Medical Holding AG (EARS) Releases Quarterly Earnings Results
www.americanbankingnews.com - August 10 at 7:46 PM
finance.yahoo.com logoAuris Medical Provides Business Update and Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 10 at 7:24 PM
finance.yahoo.com logoAuris reports 2Q loss
finance.yahoo.com - August 10 at 7:24 PM
feeds.benzinga.com logoAuris Medical Provides Business Update and Reports Second Quarter 2017 Financial Results
feeds.benzinga.com - August 10 at 6:58 AM
americanbankingnews.com logoZacks: Brokerages Anticipate Auris Medical Holding AG (EARS) Will Announce Earnings of -$0.22 Per Share
www.americanbankingnews.com - August 7 at 6:28 PM
nasdaq.com logoAuris Medical to Announce Second Quarter 2017 Financial Results and Host Conference Call on August
www.nasdaq.com - August 4 at 6:22 PM
americanbankingnews.com logoAuris Medical Holding AG (NASDAQ:EARS) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - August 4 at 3:08 PM
globenewswire.com logoAuris Medical to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 10, 2017 - GlobeNewswire (press release)
globenewswire.com - August 3 at 5:07 PM
finance.yahoo.com logoAuris Medical to Announce Second Quarter 2017 Financial Results and Host Conference Call on August 10, 2017
finance.yahoo.com - August 3 at 5:07 PM
globenewswire.com logoAuris Medical Completes Acquisition of AM-125 Assets - GlobeNewswire (press release)
www.globenewswire.com - July 20 at 3:24 PM
finance.yahoo.com logoAuris Medical Completes Acquisition of AM-125 Assets
finance.yahoo.com - July 20 at 3:24 PM
nasdaq.com logoARRY Working Its Way, Be All Ears For Auris, BGNE Inks Deal With CELG
www.nasdaq.com - July 6 at 4:51 AM
streetinsider.com logoAuris Medical Holding (EARS) Reports Complete Enrollment of Phase 3 HEALOS Trial of AM-111 for the Treatment of Sudden Deafness
www.streetinsider.com - July 6 at 4:51 AM
reuters.com logoBRIEF-Auris Medical completes enrollment of phase 3 healos trial of am-111 for the treatment of sudden deafness
www.reuters.com - July 5 at 11:49 PM
globenewswire.com logoAuris Medical Completes Enrollment of Phase 3 HEALOS Trial of AM-111 for the Treatment of Sudden Deafness - GlobeNewswire (press release)
globenewswire.com - July 5 at 6:48 PM
finance.yahoo.com logoAuris Medical Completes Enrollment of Phase 3 HEALOS Trial of AM-111 for the Treatment of Sudden Deafness
finance.yahoo.com - July 5 at 6:47 PM
americanbankingnews.com logoAuris Medical Holding AG (EARS) Coverage Initiated by Analysts at Roth Capital
www.americanbankingnews.com - July 3 at 6:25 PM
globenewswire.com logoAuris Medical to Host Scientific Symposium at IFOS ENT World Congress in Paris - GlobeNewswire (press release)
globenewswire.com - June 22 at 5:20 PM
nasdaq.com logoAuris Medical to Host Scientific Symposium at IFOS ENT World Congress in Paris - Nasdaq
www.nasdaq.com - June 22 at 10:13 AM
finance.yahoo.com logoAuris Medical to Host Scientific Symposium at IFOS ENT World Congress in Paris
finance.yahoo.com - June 22 at 10:13 AM
seekingalpha.com logoAuris Medical Holding (EARS) Updates On Clinical Stage Project Development (Key Opinion Leader Event) - Slideshow
seekingalpha.com - June 19 at 11:44 PM
americanbankingnews.com logoValuEngine Downgrades Auris Medical Holding AG (EARS) to Strong Sell
www.americanbankingnews.com - June 4 at 7:56 PM
americanbankingnews.com logoAuris Medical Holding AG (EARS) Receives Average Recommendation of "Hold" from Analysts
www.americanbankingnews.com - June 2 at 8:32 PM
globenewswire.com logoAuris Medical to Host Key Opinion Leader Event Focused on Clinical-Stage Pipeline on June 16 in New York City - GlobeNewswire (press release)
globenewswire.com - May 31 at 4:51 PM
finance.yahoo.com logoAuris Medical to Host Key Opinion Leader Event Focused on Clinical-Stage Pipeline on June 16 in New York City
finance.yahoo.com - May 31 at 9:47 AM
bizjournals.com logoHow These Biotech Stocks are Faring? -- Auris Medical, Eleven Biotherapeutics, Inotek Pharma, and Marinus Pharma
www.bizjournals.com - May 18 at 10:34 AM
americanbankingnews.com logoAuris Medical Holding AG (EARS) Sees Large Increase in Short Interest
www.americanbankingnews.com - May 16 at 7:20 AM
americanbankingnews.com logoAuris Medical Holding AG (EARS) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 12 at 11:48 AM
reuters.com logoBRIEF-Auris Medical reports Q1 loss per share chf 0.22
www.reuters.com - May 11 at 10:34 PM
finance.yahoo.com logoEdited Transcript of EARS earnings conference call or presentation 11-May-17 12:00pm GMT
finance.yahoo.com - May 11 at 10:34 PM
finance.yahoo.com logoAuris Medical Provides Business Update and Reports First Quarter 2017 Financial Results
finance.yahoo.com - May 11 at 8:57 AM
finance.yahoo.com logoInvestor Network: Auris Medical Holding AG to Host Earnings Call
finance.yahoo.com - May 11 at 8:57 AM
finance.yahoo.com logoAuris reports 1Q loss
finance.yahoo.com - May 11 at 8:57 AM
feeds.benzinga.com logoAuris Medical Provides Business Update and Reports First Quarter 2017 Financial Results
feeds.benzinga.com - May 11 at 6:43 AM
nasdaq.com logoAuris Medical Reports Key Results from Keyzilen® AMPACT1 Open ... - Nasdaq
www.nasdaq.com - May 10 at 6:40 AM
globenewswire.com logoAuris Medical Reports Key Results from Keyzilen® AMPACT1 Open ... - GlobeNewswire (press release)
globenewswire.com - May 9 at 4:50 PM

Social

Chart

Auris Medical Holding AG (EARS) Chart for Friday, September, 22, 2017

This page was last updated on 9/22/2017 by MarketBeat.com Staff